advertisement
Abstract #5822 Published in IGR 2-1
Dorzolamide and corneal recovery from edema in patients with glaucoma or ocular hypertension
Giasson CJ; Nguyen TQ; Boisjoly HM; Lesk MR; Amyot M; Charest MAmerican Journal of Ophthalmology 2000; 129:144-150
PURPOSE: To investigate whether dorzolamide alters corneal hydration control in patients with glaucoma or ocular hypertension. METHODS: Pachymetry, tonometry, and endothelial cell density were measured by a masked observer in 19 subjects with bilateral glaucoma or ocular hypertension. They were treated with 2% dorzolamide in one eye, and with saline in the other, before wearing contact lenses under patched eyes. Corneal thickness, measured each 30 minutes for up to 4.5 hours after contact lens removal, enabled estimation of percentage recovery per hour and time for 95% of corneal thickness recovery for both eyes. Seven patients repeated this test after one year of dorzolamide use, and their results were compared with those of the preceding year. RESULTS: After induction of hypoxic corneal edema, there was no significant difference between paired corneas in swelling levels (60.0±11.8 and 59.8±12.9 μm) (p=0.94), time to 95% recovery (440.6±255.8 and 445.4±186.7 minutes) (p=0.93), and percentage recovery per hour (38.1%±10.9% and 36.1%±9.6%) (p=0.40). Subjects followed up after one year of dorzolamide use did not differ significantly in values of endothelial cell density, percentage recovery per hour, or time to 95% recovery from those obtained a year before. One subject developed persistent corneal edema after his stress test in the eye treated with dorzolamide. CONCLUSIONS: There is no significant difference in the recovery from induced corneal edema after either a short-term or one-year use of dorzolamide in patients with glaucoma or ocular hypertension with a normal corneal endothelium. One patient had persistent corneal edema after the stress test was performed on the dorzolamide-treated eye.
Dr. C.J. Giasson, Guy-Bernier Research Center, Ophthalmology Research Unit, Hôpital Maisonneuve-Rosemont, School of Optometry, Université de Montreal, Quebec, Canada
Classification:
11.5.2 Topical (Part of: 11 Medical treatment > 11.5 Carbonic anhydrase inhibitors)
